All In Biotech

Drug Trial Radar · NCT06769698

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase II Randomized Study of Fianlimab Plus Cemiplimab Versus Cemiplimab Plus Placebo in First-Line Treatment of Participants With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Is Positive for PD-L1 Expression

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Apr 14, 2026

Primary completion

Jun 4, 2028

Study completion Dec 28, 2030

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Jan 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called "study drugs" in this form. The study is focused on participants with head and neck cancers who have not been previously treated for head and neck cancer that has come back or spread to other parts of the body, referred to as recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of each study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) individually (which could make the study drugs less effective or could lead to side effects) * Compatible research to better understand the study drugs and HNSCC

Conditions

  • Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

  • FDC fianlimab+cemiplimabDrug

    Fixed-Dose Combination (FDC) Administered per the protocol

  • CemiplimabDrug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate (ORR)Time frame: Up to 90 days after last study treatment, approximately 58 months

Locations

38 sites in 6 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Los Angeles, California · Recruiting

  • Samuel Oschin Cancer Center

    Los Angeles, California · Recruiting

  • Orlando Health

    Orlando, Florida · Recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Recruiting

  • Northwestern University

    Evanston, Illinois · Recruiting

  • St. Elizabeth Healthcare

    Edgewood, Kentucky · Recruiting

  • Norton Cancer Institute

    Louisville, Kentucky · Recruiting

  • Henry Ford Cancer Institute/Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • University of Rochester

    Rochester, New York · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Asplundh Cancer Pavilion

    Willow Grove, Pennsylvania · Recruiting

  • University of Tennessee Medical Center

    Knoxville, Tennessee · Recruiting

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee · Recruiting

  • Joe Arrington Cancer Research & Treatment Center

    Lubbock, Texas · Recruiting

  • Renovatio Clinical

    The Woodlands, Texas · Recruiting

  • Inova Schar Cancer Institute

    Fairfax, Virginia · Recruiting

  • Virginia Commonwealth University Massey Cancer Center

    Richmond, Virginia · Recruiting

  • Wide Bay Hospital and Health Service - Cancer Care Services - Bundaberg

    Bundaberg, Queensland, Australia · Recruiting

  • Cairns Hospital

    Cairns, Queensland, Australia · Recruiting

  • Wide Bay Hospital and Health Service

    Hervey Bay, Queensland, Australia · Recruiting

  • Peter MacCallum Cancer Centre (PMCC)

    Melbourne, Victoria, Australia · Recruiting

  • Centre Jean Perrin

    Clermont-Ferrand, Auvergne-Rhône, France · Recruiting

  • Timone Hospital - AP-HM

    Marseille, Bordeaux, France · Recruiting

  • Hopital Europeen Geroges Pompidou AP-HP

    Paris, Île-de-France Region, France · Recruiting

  • Istituto Europeo di Oncologia

    Milan, Italy · Recruiting

  • IRCCS Ospedale San Raffaele

    Milan, Lombardy, Italy · Recruiting

  • Fondazione Irccs Istituto Nazionale dei Tumori di Milano

    Milan, Lombardy, Italy · Recruiting

  • Humanitas Cancer Center

    Pieve Emanuele, Milan, Italy · Recruiting

  • Wojewodzki Szpital im. Sw. Ojca Pio

    Przemyśl, Podkarpackie Voivodeship, Poland · Recruiting

  • Centro Oncologico de Galicia

    A Coruña, Spain · Recruiting

  • University Hospital Vall d'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Andalusia, Spain · Recruiting

  • Hospital Clinic

    Barcelona, Catalonia, Spain · Recruiting

  • Complejo Hospitalario Universitario de a Coruna

    A Coruña, Galicia, Spain · Recruiting

  • Hospital Universitario de Navarra

    Pamplona, Navarre, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.